Educational use only. Check doses against the product monograph and local protocols.

milrinone

in review 2 min read Updated 2026-10-30
maintenance
0.125–0.5 mcg/kg/min
no loading dose · low end in renal impairment
HR
↑
CO
↑↑
SVR
↓
PVR
↓↓
milrinone

PDE3 inhibitor inodilator: raises contractility and lowers SVR, PCWP and PVR, independent of β-receptors. Used for low-output HF or cardiogenic shock in β-blocked patients and for RV failure with high PVR. It’s long-acting and renally cleared, so hypotension lingers, particularly in AKI. Usually needs norepinephrine alongside.

mechanism

Inhibits phosphodiesterase-3 → ↑ cAMP in myocardium (inotropy, lusitropy) and vascular smooth muscle (arterial and pulmonary vasodilation). Acts downstream of the β-receptor.


dosing

settingdose
maintenance0.125–0.5 mcg/kg/min (ACC 2025); up to 0.75 (ESC)
loading doseusually omitted (causes hypotension)
renal impairmentstart at the low end and titrate slowly; clearance falls with eGFR
onset / half-life5–15 min / ~2–2.5 h (much longer in AKI)

key points

  • β-blocked patient: works where dobutamine is blunted (ESC: PDE3i or levosimendan may be preferred)
  • RV failure / pulmonary hypertension: lowers PVR, which makes it attractive (dobutamine is the other option); combine with norepinephrine ± vasopressin to hold systemic pressure → right heart failure
  • not for septic shock: vasodilation worsens vasoplegia, and the long half-life makes it hard to undo. Dobutamine is the inotrope there → septic shock
  • vs dobutamine: equivalent outcomes (DOREMI (2021)); choose on BP, renal function, β-blockade and PVR → dobutamine
  • hypotension doesn’t resolve minutes after stopping (unlike dobutamine) → have norepinephrine ready
  • bridge only: no survival benefit in HF → cardiogenic shock

adverse effects

  • hypotension (vasodilation), worse with a bolus, hypovolaemia or AKI
  • atrial and ventricular arrhythmias
  • accumulation in renal failure → prolonged hypotension

evidence

  • DOREMI (2021) — milrinone vs dobutamine in cardiogenic shock (n=192): no difference in the composite primary outcome or its components, including in-hospital death

Prepared 2026-10-30. Not yet verified — check every number against the sources.

Key references

Suggest a correction milrinone